1868P Real-world safety of the 6-weekly pembrolizumab regimen in cancer patients treated in South East London
Matthaios Kapiris(Guy's and St Thomas' NHS Foundation Trust), A. L. Georgiou(Guy's Hospital), Christos Nikolaou(General Hospital of Athens G. Genimatas), Sophie Papa(Guy's Hospital), Samit Ghosh(Chittaranjan National Cancer Institute), Caterina Aversa(Royal Marsden NHS Foundation Trust), James Spicer(King's College London), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Mark Harries(Guy's and St Thomas' NHS Foundation Trust), Muhammad Khan(Guy's and St Thomas' NHS Foundation Trust), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Elias Pintus(Guy's and St Thomas' NHS Foundation Trust), Sarah Maria Rudman(Guy's and St Thomas' NHS Foundation Trust), L. Cain(Guy's and St Thomas' NHS Foundation Trust), L. Karapanagiotou(Guy's and St Thomas' NHS Foundation Trust), Kamarul Zaki(Guy's and St Thomas' NHS Foundation Trust), Deborah Enting(Guy's and St Thomas' NHS Foundation Trust)
Cited by 0
Related Papers
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
|The Lancet|2019|287
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
|Annals of Oncology|2018|252